M

    Milestone Pharmaceuticals Inc (MIST)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.16
    +0.00 (+0.00%)

    Market Cap: $144.42M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(20/30)
    Avg Surprise
    +3.04%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.26 - $-0.18
    4 analysts
    EPS Revisions
    1
    0
    7d
    1
    2
    30d
    EPS Estimate Drift
    90d ago$-0.20+3.6%
    60d ago$-0.21+0.0%
    30d ago$-0.21+0.0%
    7d ago$-0.21+0.0%
    Current$-0.21
    Revenue Consensus
    $2M
    Range$500000 - $2M
    6 analysts
    Dec 31, 2026
    EPS Consensus$-0.62
    Range$-0.69 - $-0.56
    5 analysts
    Revenue Consensus
    $-36194780
    Range$-37222920 - $-34022920
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.62---
    Sep 26EST
    		-$-0.21---
    Jun 26
    		$-0.21$-0.18-16.67%Miss-5.0%
    Mar 26
    		$-0.20$0.19-205.26%Miss+35.5%
    Dec 25
    		$-0.15$-0.16+6.25%Beat+21.1%
    Sep 25
    		$-0.12$-0.17+29.41%Beat+14.3%
    Jun 25
    		$-0.20$-0.18-11.11%Miss-42.9%
    Mar 25
    		$-0.31$-0.19-63.16%Miss-47.6%
    Dec 24
    		$-0.19$-0.15-26.67%Miss+40.6%
    Sep 24
    		$-0.14$-0.18+22.22%Beat+60.0%
    Jun 24
    		$-0.14$-0.20+30.00%Beat+62.2%
    Mar 24
    		$-0.21$-0.27+22.22%Beat+40.0%
    Dec 23
    		$-0.32$-0.31-3.23%Miss-3.2%
    Sep 23
    		$-0.35$-0.39+10.26%Beat-2.9%
    Jun 23
    		$-0.37$-0.39+5.13%Beat+5.1%
    Mar 23
    		$-0.35$-0.39+10.26%Beat-6.1%
    Dec 22
    		$-0.31$-0.33+6.06%Beat+22.5%
    Sep 22
    		$-0.34$-0.41+17.07%Beat+0.0%
    Jun 22
    		$-0.39$-0.37-5.41%Miss-2050.0%
    Mar 22
    		$-0.33$-0.38+13.16%Beat-10.0%
    Dec 21
    		$-0.40$-0.36-11.11%Miss-207.7%
    Sep 21
    		$-0.34$-0.35+2.86%Beat+15.0%
    Jun 21
    		$0.02N/A+105.71%Beat+103.8%
    Mar 21
    		$-0.30$-0.32+6.25%Beat+55.2%
    Dec 20
    		$-0.13N/A+68.29%Beat+79.4%
    Sep 20
    		$-0.40$-0.46+13.04%Beat+23.1%
    Jun 20
    		$-0.53$-0.43-23.26%Miss+5.4%
    Mar 20
    		$-0.67$-0.74+9.46%Beat-63.4%
    Dec 19
    		$-0.63$-0.51-23.53%Miss-
    Sep 19
    		$-0.52$-0.55+5.45%Beat-
    Jun 19
    		$-0.56$-0.56+0.00%Beat-
    Mar 19
    		$-0.41N/A+97.63%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.71EV/EBITDA-1.43x
    Price/FCF-2.34xFCF Yield-42.69%
    Profitability
    Profit Margin0.00%Operating Margin-4585.00%
    ROE-35523.00%ROIC-79.97%
    Financial Health
    Debt/Equity3.25xInterest Coverage-7.25x
    Current Ratio8.13xQuick Ratio7.92x
    Trading Statistics
    Beta0.98Avg Volume1.67M
    52-Week High$3.0652-Week Low$1.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.11
    SMA 20$1.14
    SMA 50$1.19
    SMA 200$1.68
    EMA 10$1.14
    EMA 20$1.14
    EMA 50$1.21
    EMA 200$1.51

    MACD

    Line: -0.01Signal: -0.03Hist: 0.01

    ADX

    ADX: 19.2+DI: 26.1-DI: 22.8

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down8.0
    PSAR$1.03

    Bollinger Bands

    Upper Band$1.28
    Lower Band$1.00
    %B Position2440%(Upper)
    Band Width0.58

    RSI (14-Day)

    Neutral
    51.0

    Momentum Oscillators

    Stoch %K58.1
    Stoch %D58.1
    Williams %R-40.4
    ROC (10d)5.5%
    Momentum0.06
    CCI (20d)24.9
    MFI (14d)29.5

    Volatility Measures

    ATR (14d)$0.07(6.2%)
    StdDev (20d)0.07
    Hist Vol72.7%(High)

    Volume Flow

    VWAP$1.16
    OBV-168.9M
    AD Line-81.5M
    CMF (20d)0.021

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio0.6x
    VWMA (20d)$1.12

    Pivot Points

    R3$1.26
    R2$1.23
    R1$1.20
    Pivot Point$1.17
    S1$1.13
    S2$1.10
    S3$1.07

    Advanced Oscillators

    TSI-5.07
    Ultimate Osc55.0
    KST-64.93

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$559,000$238,000$1.55M$0$0$0$108,000$0$0$0$-868,002$0
    Cost of Revenue$32,000$14,000$34,000$0$0$0$567,000$0$0$0$532,000$0
    Gross Profit$527,000$224,000$1.55M$0$0$0$-567,000$0$0$0$-1,400,002$0
    Operating Expenses$26.16M$23.89M$18.80M$11.83M$12.53M$20.52M$12.35M$9.62M$9.66M$10.48M$13.80M$15.36M
    R&D$3.51M$3.25M$5.52M$3.94M$3.67M$4.98M$3.94M$3.96M$2.81M$3.64M$5.45M$6.72M
    SG&A$22.65M$4.82M$5.08M$3.26M$8.86M$5.17M$4.00M$3.74M$5.05M$3.95M$3.37M$4.23M
    Operating Income$-25,630,000$-23,663,000$-17,257,000$-11,829,000$-12,531,000$-20,523,000$-12,348,000$-9,616,000$-9,662,000$-10,476,000$-13,800,000$-15,360,000
    Interest Income$1.74M$1.73M$833,000$874,000$516,000$697,000$904,000$1.08M$1.19M$994,000$1.05M$1.12M
    Interest Expense$4.72M$4.13M$985,000$967,000$951,000$935,000$919,000$903,000$887,000$872,000$860,000$841,000
    Income Before Tax$-28,614,000$-26,066,000$-17,409,000$-11,922,000$-12,966,000$-20,761,000$-12,363,000$-9,439,000$-9,363,000$-10,354,000$-13,611,000$-15,081,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-28,614,000$-26,066,000$-17,409,000$-11,922,000$-12,966,000$-20,761,000$-12,363,000$-9,439,000$-9,363,000$-10,354,000$-13,611,000$-15,081,000
    EBITDA$-25,455,000$-23,490,000$-17,108,000$-11,695,000$-12,397,000$-20,394,000$-12,225,000$-9,496,000$-9,545,000$-10,361,000$-13,690,000$-15,256,000
    EBIT$-25,630,000$-23,663,000$-17,257,000$-11,829,000$-12,531,000$-20,523,000$-12,348,000$-9,616,000$-9,662,000$-10,476,000$-13,800,000$-15,360,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MIST

    News

    Cantor Fitzgerald Initiates Milestone Pharmaceuticals(MIST.US) With Buy Rating, Announces Target Price $3

    Cantor Fitzgerald has initiated coverage on Milestone Pharmaceuticals (MIST.US) with a "Buy" rating. The firm has also set a price target of $3 for the company's stock.

    Moomoo•8/21/26•
    Bullish

    Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial

    Milestone Pharmaceuticals (NASDAQ:MIST) saw its shares increase by 3.9% after announcing the enrollment of the first patient in its Phase 3 ReVeRA-301 study for etripamil, targeting atrial fibrillation with rapid ventricular rate (AFib-RVR). This trial aims to expand the use of etripamil beyond its current approval for paroxysmal supraventricular tachycardia (PSVT). The study evaluates a 70 mg etripamil regimen and builds on positive results from an earlier Phase 2 trial, with Milestone planning to seek a supplemental New Drug Application for AFib-RVR, potentially for self-administration.

    Yahoo Finance•8/21/26•
    Bullish

    Milestone Pharmaceuticals begins phase 3 trial for AFib treatment

    Milestone Pharmaceuticals (NASDAQ: MIST) has initiated a Phase 3 clinical trial, ReVeRA-301, for its etripamil nasal spray to treat atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial will test the same 70 mg repeat-dose regimen previously approved for PSVT and aims to enroll approximately 150 patients. This study builds on positive Phase 2 results and targets a single-study supplemental new drug application pathway, addressing a condition that frequently leads to emergency room visits.

    Investing.com•8/21/26•
    Bullish

    Milestone Pharmaceuticals stock gains on Phase 3 AFib trial

    Milestone Pharmaceuticals (NASDAQ: MIST) shares rose 3.9% after the company announced it had enrolled the first patient in its Phase 3 ReVeRA-301 trial for etripamil, targeting atrial fibrillation with rapid ventricular rate (AFib-RVR). This trial uses the same 70 mg repeat-dose regimen that was FDA-approved for PSVT and aims to reduce ventricular rate and improve symptoms in AFib-RVR patients. The company is pursuing a supplemental new drug application registration pathway, allowing patients to self-administer the treatment at home, addressing a significant medical need given the rising economic burden of AFib in the U.S.

    Investing.com•8/21/26•
    Bullish

    Cantor Fitzgerald initiates Milestone Pharmaceuticals stock coverage with overweight rating

    Cantor Fitzgerald has initiated coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with an overweight rating and a $3.00 price target, citing potential for its drug Cardamyst in paroxysmal supraventricular tachycardia (PSVT) and a significant untapped opportunity in atrial fibrillation with rapid ventricular response (AFib-RVR). The firm believes the market is currently undervaluing Milestone, particularly its AFib-RVR program, and forecasts substantial sales growth for Cardamyst. Despite a recent Q2 loss exceeding expectations, early sales of CARDAMYST show promise, with Cantor Fitzgerald projecting a 200% upside to their price target.

    Investing.com Canada•8/20/26•
    Bullish

    Frequently Asked Questions About MIST

    Does MIST pay dividends?
    Milestone Pharmaceuticals Inc (MIST) does not currently pay a regular dividend.
    What is MIST's market cap?
    Milestone Pharmaceuticals Inc (MIST) has a market capitalization of $144.42M with a current stock price of $1.16.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In